Hamidreza Montazeri Aliabadi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6373551/publications.pdf

Version: 2024-02-01

30 papers

1,042 citations

16 h-index 30 g-index

30 all docs 30 docs citations

30 times ranked

1527 citing authors

#	Article	IF	Citations
1	"Do We Know Jack―About JAK? A Closer Look at JAK/STAT Signaling Pathway. Frontiers in Oncology, 2018, 8, 287.	2.8	283
2	Polymeric micelles for the solubilization and delivery of cyclosporine A: pharmacokinetics and biodistribution. Biomaterials, 2005, 26, 7251-7259.	11.4	123
3	Impact of Lipid Substitution on Assembly and Delivery of siRNA by Cationic Polymers. Macromolecular Bioscience, 2011, 11, 662-672.	4.1	77
4	Prospects for RNAi Therapy of COVID-19. Frontiers in Bioengineering and Biotechnology, 2020, 8, 916.	4.1	69
5	Induction of Apoptosis by Survivin Silencing through siRNA Delivery in a Human Breast Cancer Cell Line. Molecular Pharmaceutics, 2011, 8, 1821-1830.	4.6	61
6	Effective response of doxorubicin-sensitive and -resistant breast cancer cells to combinational siRNA therapy. Journal of Controlled Release, 2013, 172, 219-228.	9.9	56
7	Effective down-regulation of Breast Cancer Resistance Protein (BCRP) by siRNA delivery using lipid-substituted aliphatic polymers. European Journal of Pharmaceutics and Biopharmaceutics, 2012, 81, 33-42.	4.3	33
8	Combinational siRNA delivery using hyaluronic acid modified amphiphilic polyplexes against cell cycle and phosphatase proteins to inhibit growth and migration of triple-negative breast cancer cells. Acta Biomaterialia, 2018, 66, 294-309.	8.3	31
9	Identification of Potential Drug Targets in Cancer Signaling Pathways using Stochastic Logical Models. Scientific Reports, 2016, 6, 23078.	3.3	24
10	Nanomedicine for immunosuppressive therapy: achievements in pre-clinical and clinical research. Expert Opinion on Drug Delivery, 2018, 15, 397-418.	5.0	23
11	Effective downâ€regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipidâ€substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. Journal of Biomedical Materials Research - Part A, 2014, 102, 3216-3228.	4.0	22
12	Targeting Cell Cycle Proteins in Breast Cancer Cells with siRNA by Using Lipid-Substituted Polyethylenimines. Frontiers in Bioengineering and Biotechnology, 2015, 3, 14.	4.1	21
13	Multiple siRNA delivery against cell cycle and anti-apoptosis proteins using lipid-substituted polyethylenimine in triple-negative breast cancer and nonmalignant cells. Journal of Biomedical Materials Research - Part A, 2016, 104, 3031-3044.	4.0	20
14	Tumor-targeted delivery of siRNA using fatty acyl-CGKRK peptide conjugates. Scientific Reports, 2017, 7, 6093.	3.3	20
15	Amphiphilic Peptides for Efficient siRNA Delivery. Polymers, 2019, 11, 703.	4.5	19
16	Single and Combinational siRNA Therapy of Cancer Cells: Probing Changes in Targeted and Nontargeted Mediators after siRNA Treatment. Molecular Pharmaceutics, 2016, 13, 4116-4128.	4.6	17
17	A systematic comparison of lipopolymers for siRNA delivery to multiple breast cancer cell lines: In vitro studies. Acta Biomaterialia, 2020, 102, 351-366.	8.3	17
18	The Immunosuppressive Activity of Polymeric Micellar Formulation of Cyclosporine A: In Vitro and In Vivo Studies. AAPS Journal, 2011, 13, 159-168.	4.4	16

2

#	Article	IF	CITATIONS
19	Effect of siRNA pre-Exposure on Subsequent Response to siRNA Therapy. Pharmaceutical Research, 2015, 32, 3813-3826.	3.5	14
20	Design and application of hybrid cyclic-linear peptide-doxorubicin conjugates as a strategy to overcome doxorubicin resistance and toxicity. European Journal of Medicinal Chemistry, 2021, 226, 113836.	5.5	14
21	Alzheimer's Disease: Dawn of a New Era?. Journal of Pharmacy and Pharmaceutical Sciences, 2017, 20, 184.	2.1	13
22	Effective down-regulation of signal transducer and activator of transcription 3 (STAT3) by polyplexes of siRNA and lipid-substituted polyethyleneimine for sensitization of breast tumor cells to conventional chemotherapy. Journal of Biomedical Materials Research - Part A, 2013, 102, n/a-n/a.	4.0	13
23	Peptide/Lipid-Associated Nucleic Acids (PLANAs) as a Multicomponent siRNA Delivery System. Molecular Pharmaceutics, 2021, 18, 986-1002.	4.6	11
24	Difatty Acyl-Conjugated Linear and Cyclic Peptides for siRNA Delivery. ACS Omega, 2017, 2, 6939-6957.	3.5	10
25	Heterogeneity and Plasticity of Human Breast Cancer Cells in Response to Molecularly-Targeted Drugs. Frontiers in Oncology, 2019, 9, 1070.	2.8	9
26	[(WR)8WK \hat{l}^2 A]-Doxorubicin Conjugate: A Delivery System to Overcome Multi-Drug Resistance against Doxorubicin. Cells, 2022, 11, 301.	4.1	8
27	Redox-Responsive Disulfide Cyclic Peptides: A New Strategy for siRNA Delivery. Molecular Pharmaceutics, 2022, 19, 1338-1355.	4.6	6
28	In vitro and ex-vivo evaluation of topical formulations designed to minimize transdermal absorption of Vitamin K1. PLoS ONE, 2018, 13, e0204531.	2.5	4
29	Suppression of Human Coronavirus 229E Infection in Lung Fibroblast Cells via RNA Interference. Frontiers in Nanotechnology, 2021, 3, .	4.8	4
30	Combinational silencing of components involved in JAK/STAT signaling pathway. European Journal of Pharmaceutical Sciences, 2022, 175, 106233.	4.0	4